Document Detail

Anaphylactoid reactions associated with ondansetron.
MedLine Citation:
PMID:  7803876     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To describe two patients with anaphylactoid-type reactions to ondansetron. CASE SUMMARY: A 41-year-old man with grade III leiomyosarcoma of the right tibia was admitted to the hospital for his second dose of first-cycle neoadjuvant intraaterial cisplatin 60 mg/m2 therapy. He experienced an anaphylactoid reaction following intravenous ondansetron infusion that was confirmed on rechallenge. In a second case, premedication with intravenous ondansetron resulted in an anaphylactoid reaction in a 44-year-old woman with stage III ovarian cancer receiving her ninth course of cyclophosphamide and carboplatin. Both patients had received ondansetron previously with no adverse effects. DISCUSSION: Peer-reviewed journal articles and reports, obtained through a MEDLINE search, were reviewed. Information on the individual cases was obtained from the patients' medical records. Preservative changes in ondansetron infusion were examined as possible causes of the anaphylactoid reactions in our patients, but no conclusive data linking them were found. CONCLUSIONS: The efficacy and safety of ondansetron has led to the widespread use of this medication in the treatment of nausea and vomiting caused by cancer chemotherapy and radiation therapy. Practitioners should be made aware that acute severe anaphylactoid reactions could occur in patients who have previously received ondansetron with no adverse effects.
J L Kossey; K K Kwok
Related Documents :
23812226 - Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with ...
24159596 - Surgical strategy for liver cancers in the era of effective chemotherapy.
23257676 - Successful treatment with sorafenib for primary refractory acute monoblastic leukemia w...
24058496 - Adjuvant chemotherapy, a valuable alternative option in selected patients with cervical...
18591436 - Transcriptomic biomarkers for individual risk assessment in new-onset heart failure.
11135046 - Evaluation of dna topoisomerase iialpha expression provides independent prognostic info...
Publication Detail:
Type:  Case Reports; Comparative Study; Journal Article    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  28     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-02-02     Completed Date:  1995-02-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1029-30     Citation Subset:  IM    
Department of Pharmacy, University of Washington Medical Center, Seattle 98159.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anaphylaxis / chemically induced*
Antineoplastic Combined Chemotherapy Protocols
Bone Neoplasms / drug therapy
Carboplatin / adverse effects,  therapeutic use
Cisplatin / adverse effects,  therapeutic use
Cyclophosphamide / adverse effects,  therapeutic use
Infusions, Intravenous
Leiomyosarcoma / drug therapy
Nausea / chemically induced,  prevention & control
Ondansetron / administration & dosage,  adverse effects*
Ovarian Neoplasms / drug therapy
Reg. No./Substance:
15663-27-1/Cisplatin; 41575-94-4/Carboplatin; 50-18-0/Cyclophosphamide; 99614-02-5/Ondansetron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didano...
Next Document:  Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the t...